AHS Cancer Control Alberta
AHS Cancer Control Alberta
Explore linked clinical trials.37 results ยท Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| mHealth Physical Activity Intervention for Young Cancer Survivors | cancer, neoplasm | Active, not recruiting | Not applicable | 2026-09-25 | NCT04765241 | |
| Radiation Treatment of the Prostate That is Specially Adjusted for Each Person | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 | 2026-09-03 | NCT07578519 | |
| Study of Niacin in Glioblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-03 | NCT04677049 | |
| Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer | Digestive System Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive, colitis, colonic disorder, diarrheal disease, digestive system disorder, gastroenteritis, intestinal disorder | Recruiting | Phase 2 / Phase 3 | 2026-08-27 | NCT06337695 | |
| Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis | Infections, lung disorder, pneumonia, pneumonitis, respiratory system disorder, respiratory tract infectious disorder | Recruiting | Phase 2 | 2026-08-07 | NCT06860542 | |
| GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02) | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, alveolar soft part sarcoma, myomatous neoplasm, neoplasm, sarcoma | Active, not recruiting | Early phase 1 | 2026-03-23 | NCT06789081 | |
| Steroid Sparing in Immune Related Hepatitis (irH) | Hepatitis Immune | Recruiting | Not applicable | 2026-03-23 | NCT05345847 | |
| Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-02-13 | NCT04765514 | |
| COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer | Advanced Differentiated Thyroid Gland Carcinoma | Not yet recruiting | Phase 2 | 2026-02-06 | NCT06790589 | |
| Loratadine for the Prevention of G-CSF-related Bone Pain | Stem Cell Transplant Complications | Recruiting | Phase 2 | 2026-02-05 | NCT05421416 | |
| Stereotactic Body Radiation Therapy (SBRT) and Immunotherapy for Oligometastatic Esophageal Cancer | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, neoplasm | Not yet recruiting | Phase 2 | 2026-01-09 | NCT07330583 | |
| PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Not yet recruiting | Phase 2 | 2025-12-18 | NCT07291557 | |
| Chemoradiotherapy for Advanced Esophageal Cancer | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, neoplasm | Recruiting | Phase 2 | 2025-12-16 | NCT02297217 | |
| Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Not yet recruiting | Phase 2 | 2025-12-15 | NCT05128734 | |
| A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell myeloma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2025-12-15 | NCT04268199 | |
| This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 | 2025-12-08 | NCT06882174 | |
| Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer | anal canal cancer | Recruiting | Phase 2 | 2025-10-02 | NCT05040815 | |
| SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 2 | 2025-06-27 | NCT05775146 | |
| Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo) | Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive, diarrheal disease | Recruiting | Phase 2 | 2025-06-27 | NCT05663775 | |
| A Nutritional Supplement to Support People With Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Not applicable | 2025-06-27 | NCT04175769 | |
| Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, biliary tract cancer, biliary tract disorder, carcinoma, cholangiocarcinoma, endocrine system disorder, epithelial neoplasm, liver disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 2 | 2025-06-26 | NCT05451043 | |
| Tamoxifen Versus Etoposide After First Recurrence in GBM Patients | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2025-06-26 | NCT04765098 | |
| Trial of Combined Radiotherapy and Vertebroplasty for Patients With Painful Metastatic Spinal Lesions | Spinal Metastases | Recruiting | Phase 2 | 2025-06-26 | NCT04242589 | |
| Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2025-06-26 | NCT03831178 | |
| A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer | Unresectable Biliary Tract Cancer | Active, not recruiting | Phase 2 | 2025-06-26 | NCT02632305 |